iADC
iADC
)
Technology
IADC
In addition to direct anti-tumor activity of the conjugates, NBE-Therapeutics' ADCs have been found to induce a sustained and long-lasting anti-tumor immunity in tumor models with a fully functional adaptive immune system. This does not only result in the complete regression of tumors in syngeneic mouse tumor models, but after complete regression of the tumors in such models, the mice are entirely protected against tumor re-challenge with the same tumor cells.
It can reasonably be expected that some of the immune-oncology function of NBE-Therapeutics' iADCs can be translated into the clinical setting, where existing immune-modulating therapies can further be improved or enhanced, in order to achieve sustained and durable anti-tumor responses.